Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.82
-2.7%
$1.98
$0.98
$3.44
$75.42M0.2226,656 shs9,682 shs
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$1.27
$1.28
$0.92
$22.50
$76.57M0.6480,746 shsN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.50
-2.5%
$3.64
$2.57
$6.77
$22.18M0.575,901 shs2,276 shs
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.23
$1.41
$0.81
$1.84
$65.18M1.522.47 million shs1.68 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-2.67%-2.15%-9.00%-34.77%-15.74%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
0.00%0.00%0.00%+4.96%-89.18%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-2.51%-2.78%-7.16%+1.19%-45.14%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
0.00%-15.75%-19.08%+13.89%-18.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.82
-2.7%
$1.98
$0.98
$3.44
$75.42M0.2226,656 shs9,682 shs
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$1.27
$1.28
$0.92
$22.50
$76.57M0.6480,746 shsN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.50
-2.5%
$3.64
$2.57
$6.77
$22.18M0.575,901 shs2,276 shs
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.23
$1.41
$0.81
$1.84
$65.18M1.522.47 million shs1.68 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-2.67%-2.15%-9.00%-34.77%-15.74%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
0.00%0.00%0.00%+4.96%-89.18%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-2.51%-2.78%-7.16%+1.19%-45.14%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
0.00%-15.75%-19.08%+13.89%-18.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
0.00
N/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1.89
Reduce$4.89284.95% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
3.00
Buy$5.50347.15% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/A($0.37) per shareN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$145.05M0.53N/AN/A$1.67 per share0.76
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/A$3.40 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$11.12MN/A0.00N/AN/AN/AN/A11/6/2025 (Estimated)
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$195.79M-$0.90N/AN/AN/A-36.81%-93.35%-24.15%11/14/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$58.71M-$1.57N/AN/AN/AN/A-47.94%-43.82%11/6/2025 (Estimated)

Latest NAII, BYSI, PMVP, and IGMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A-$0.04N/A-$0.04N/AN/A
8/7/2025Q2 2025
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.39-$0.41-$0.02-$0.41N/AN/A
7/31/2025Q2 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.30$1.58+$1.88$1.58$3.20 million$143.62 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
2.19
2.19
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/A
17.66
17.66
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/A
12.52
12.52

Institutional Ownership

CompanyInstitutional Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
42.79%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
90.20%

Insider Ownership

CompanyInsider Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
57.00%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
7.57%
CompanyEmployeesShares OutstandingFree FloatOptionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8040.33 million28.51 millionOptionable
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
19060.29 million25.93 millionOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
5052.99 million48.98 millionOptionable

Recent News About These Companies

Pmv Pharmaceuticals Inc (PMVP) - Investing.com
PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)
PMV Pharmaceuticals sees cash runway to end of 2026
PMV Pharmaceuticals files $200M mixed securities shelf

New MarketBeat Followers Over Time

Media Sentiment Over Time

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$1.82 -0.05 (-2.67%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.81 -0.01 (-0.55%)
As of 09/12/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

IGM Biosciences stock logo

IGM Biosciences NASDAQ:IGMS

$1.27 0.00 (0.00%)
As of 08/14/2025

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.55 -0.04 (-1.11%)
As of 09/12/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

PMV Pharmaceuticals stock logo

PMV Pharmaceuticals NASDAQ:PMVP

$1.23 0.00 (0.00%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.24 +0.01 (+0.41%)
As of 09/12/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.